Blocking IL6 signaling was shown capable of rewiring the chemotherapeutic resistance of pancreatic cancers in vivo,175 with a clinical trial involving 140 advanced pancreatic cancer patients being launched to examine the efficacy of tocilizumab (an IL6R inhibitor) in improving the chemotherapeutic outcome (NCT02767557). This evidence concerns the gene IL6 and pancreatic neoplasm.